Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,743,798

« Back to Dashboard
Patent 6,743,798 protects ADEMPAS and is included in one NDA.

This patent has thirty-four patent family members in thirty countries.

Summary for Patent: 6,743,798

Title: Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
Abstract:The present invention relates to novel substituted pyrazole derivatives of the general formula (I) ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and A are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.
Inventor(s): Straub; Alexander (Wuppertal, DE), Feurer; Achim (Odenthal, DE), Alonso-Alija; Cristina (Haan, DE), Stasch; Johannes-Peter (Solingen, DE), Perzborn; Elisabeth (Wuppertal, DE), Hutter; Joachim (Wuppertal, DE), Dembowsky; Klaus (Boston, MA), Stahl; Elke (Bergisch Gladbach, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:09/744,830
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 6th percentile
Forward Citations: 4th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
TABLET;ORAL204819-001Oct 8, 2013RXYesNo6,743,798► subscribeYY
Bayer Hlthcare
TABLET;ORAL204819-002Oct 8, 2013RXYesNo6,743,798► subscribeYY
Bayer Hlthcare
TABLET;ORAL204819-003Oct 8, 2013RXYesNo6,743,798► subscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,743,798

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany198 34 044Jul 29, 1998
PCT Information
PCT FiledJuly 16, 1999PCT Application Number:PCT/EP99/05074
PCT Publication Date:February 10, 2000PCT Publication Number: WO00/06569

International Patent Family for Patent: 6,743,798

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey200100238► subscribe
El Salvador1999000118► subscribe
Slovakia1302001► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.